肠道菌群在糖尿病肾病发生发展中的作用及机制研究进展

doi:10.3969/j.issn.1006-7795.2025.04.024

摘要/Abstract

摘要： 糖尿病肾病（diabetic nephropathy，DN）是糖尿病最常见、最严重的并发症之一，同时也是慢性肾病和终末期肾病（end stage renal disease，ESRD）的主要原因之一，严重影响患者生活质量。目前，DN的标准管理策略主要包括严格的血糖、血压控制以及使用肾素-血管紧张素-醛固酮系统抑制剂，这些治疗可以延缓DN进展，但不能阻止其最终进展为ESRD。近年来，肠肾轴在DN发生发展中的作用受到了越来越多的关注。DN患者肠道菌群多样性发生改变，并通过代谢物与宿主之间相互作用，在DN发病机制及治疗中起关键作用。本综述旨在讨论肠道菌群参与DN的关键机制及靶向肠道菌群的治疗策略，以期为DN的临床治疗提供新的见解。

关键词: 糖尿病肾病, 肠道菌群, 肠肾轴, 代谢产物, 益生菌, 粪菌移植

Abstract: Diabetic nephropathy (DN) ranks as a frequent and serious complication in diabetes mellitus, and it's a key factor in chronic kidney disease and end-stage renal disease(ESRD), greatly diminishing the life quality of patients. Presently, the conventional treatment approaches for DN mainly involve strict regulation of blood sugar and pressure, in conjunction with the application of renin-angiotensin-aldosterone system inhibitors. While these therapies can slow down the advancement of DN, they are ineffective in stopping its final development into ESRD. Lately, the involvement of the gut-kidney axis in the development and advancement of DN has attracted growing interest. Individuals suffering from DN show changes in the variety of gut microbiota, which are crucial in the development and management of DN due to metabolic interactions with the host. The goal of this analysis is to explore the fundamental processes of gut microbiota's role in DN and explore treatment approaches focusing on gut microbiota, aiming to offer new perspectives for the clinical handling of DN.

Key words: diabetic nephropathy, gut microbiota, gut-kidney axis, metabolites, probiotics, fecal microbiota transplantation

中图分类号:

R587.2

韩梅, 张刚, 赵晋, 王安静, 惠月清, 孙世仁. 肠道菌群在糖尿病肾病发生发展中的作用及机制研究进展[J]. 首都医科大学学报, 2025, 46(4): 742-748.

Han Mei, , Zhang Gang , Zhao Jin , Wang Anjing , Hui Yueqing , Sun Shiren. The role and mechanism of gut microbiota in the development of diabetic nephropathy[J]. Journal of Capital Medical University, 2025, 46(4): 742-748.

参考文献

［1］Sun H, Saeedi P, Karuranga S, et al. Erratum to"IDF diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045"［diabetes Res.Clin.pract.183(2022)109119］［J］. Diabetes Res Clin Pract 2023, 204: 110945.
［2］Afkarian M, Zelnick L R, Hall Y N, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988－2014［J］. JAMA, 2016, 316(6): 602－610.
［3］Wal P, Tyagi S, Pal R S, et al. A strategic investigation on diabetic nephropathy; its conceptual model and clinical manifestations: a review［J］. Curr Diabetes Rev, 2023, 19(5): e260422204036.
［4］Jiang G Z, Luk A O Y, Tam C H T, et al. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes［J］. Kidney Int, 2019, 95(1): 178－187.
［5］D'Alessandro V F, Takeshita A, Yasuma T, et al. Transforming growth factorβ1 overexpression is associated with insulin resistance and rapidly progressive kidney fibrosis under diabetic conditions［J］. Int J Mol Sci, 2022, 23(22): 14265.
［6］Ricciardi C A, Gnudi L. Kidney disease in diabetes: from mechanisms to clinical presentation and treatment strategies［J］. Metabolism, 2021, 124: 154890.
［7］Noecker C, Turnbaugh P J. Emerging tools and best practices for studying gut microbial community metabolism［J］. Nat Metab, 2024, 6(7): 1225－1236.
［8］Heintz-Buschart A, Wilmes P. Human gut microbiome: function matters［J］. Trends Microbiol, 2018, 26(7): 563－574.
［9］Yang G, Wei J L, Liu P Y, et al. Role of the gut microbiota in type 2 diabetes and related diseases［J］. Metabolism, 2021, 117: 154712.
［10］Johnson E L, Heaver S L, Walters W A, et al. Microbiome and metabolic disease: revisiting the bacterial phylum Bacteroidetes［J］. J Mol Med, 2017, 95(1): 1－8.
［11］Giordano L, Mihaila S M, Eslami Amirabadi H, et al. Microphysiological systems to recapitulate the gut-kidney axis［J］. Trends Biotechnol, 2021, 39(8): 811－823.
［12］Vallianou N G, Kounatidis D, Panagopoulos F, et al. Gut microbiota and its role in the brain-gut-kidney axis in hypertension［J］. Curr Hypertens Rep, 2023, 25(11): 367－376.
［13］Wang X F, Yang S T, Li S H, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents［J］. Gut, 2020, 69(12): 2131－2142.
［14］Graboski A L, Redinbo M R. Gut-derived protein-bound uremic toxins［J］. Toxins, 2020, 12(9): 590.
［15］Linh H T, Iwata Y, Senda Y, et al. Intestinal bacterial translocation contributes to diabetic kidney disease［J］. J Am Soc Nephrol, 2022, 33(6): 1105－1119.
［16］Lambie M, Bonomini M, Davies S J, et al. Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis［J］. Trends Endocrinol Metab, 2021, 32(9): 721－730.
［17］Takeuchi T, Kubota T, Nakanishi Y, et al. Gut microbial carbohydrate metabolism contributes to insulin resistance［J］. Nature, 2023, 621(7978): 389－395.
［18］Greenhill C. Gut microbiota: Firmicutes and Bacteroidetes involved in insulin resistance by mediating levels of glucagon-like peptide 1［J］. Nat Rev Endocrinol, 2015, 11(5): 254.
［19］Ma P, Zhang Y, Yin Y J, et al. Gut microbiota metabolite tyramine ameliorates high-fat diet-induced insulin resistance via increased Ca2+ signaling［J］. EMBO J, 2024, 43(16): 3466－3493.
［20］Yue S J, Liu J, Wang A T, et al. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids［J］. Am J Physiol Endocrinol Metab, 2019, 316(1): E73-E85.
［21］Zhai L X, Xiao H T, Lin C Y, et al. Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome［J］. Nat Commun, 2023, 14(1): 4986.
［22］Saad M J A, Santos A, Prada P O. Linking gut microbiota and inflammation to obesity and insulin resistance［J］. Physiology, 2016, 31(4):283－293.
［23］Guo Y L, Xie G X, Zhang X Y. Role of FXR in renal physiology and kidney diseases［J］. Int J Mol Sci, 2023, 24(3): 2408.
［24］She J Q, Tuerhongjiang G, Guo M Y, et al. Statins aggravate insulin resistance through reduced blood glucagon-like peptide－1 levels in a microbiota-dependent manner［J］. Cell Metab, 2024, 36(2): 408－421, e5.
［25］Naaman S C, Bakris G L. Diabetic nephropathy: update on pillars of therapy slowing progression［J］. Diabetes Care, 2023, 46(9): 1574－1586.
［26］Jaworska K, Koper M, Ufnal M. Gut microbiota and renin-angiotensin system: a complex interplay at local and systemic levels［J］. Am J Physiol Gastrointest Liver Physiol, 2021, 321(4): G355-G366.
［27］Naaman S C, Bakris G L. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression［J］. Diabetes care，2023，46（9）： 1574－1586.
［28］Lu C C, Hu Z B, Wang R, et al. Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy［J］. Acta Pharmacol Sin, 2020, 41(8): 1111－1118.
［29］Vanholder R, Schepers E, Pletinck A, et al. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review［J］. J Am Soc Nephrol, 2014,25(9):1897－907.
［30］Lohia S, Valkenburg S, Stroggilos R, et al. Investigation of the human-gut-kidney axis by fecal proteomics, highlights molecular mechanisms affected in CKD［J］. Heliyon, 2024, 10(12): e32828.
［31］Lu C C, Ma K L, Ruan X Z, et al. Intestinal dysbiosis activates renal renin-angiotensin system contributing to incipient diabetic nephropathy［J］. Int J Med Sci, 2018, 15(8): 816－822.
［32］Liu W, Tan Z N, Geng M R, et al. Impact of the gut microbiota on angiotensin Ⅱ-related disorders and its mechanisms［J］. Biochem Pharmacol, 2023, 214: 115659.
［33］Brennan E, Kantharidis P, Cooper ME, et al. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function［J］. Nat Rev Nephrol. 2021 Nov;17(11):725－739.
［34］Mishra S P, Wang B, Jain S, et al. A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut［J］. Gut, 2023, 72(10): 1848－1865.
［35］Wang L, Zhu Q, Lu A H, et al. Sodium butyrate suppresses angiotensin II-induced hypertension by inhibition of renal (pro)renin receptor and intrarenal renin-angiotensin system［J］. J Hypertens, 2017, 35(9): 1899－1908.
［36］Chen Z Q, Liang W J, Liang J, et al. Probiotics: functional food ingredients with the potential to reduce hypertension［J］. Front Cell Infect Microbiol, 2023, 13: 1220877.
［37］Zhao L, Hu H R, Zhang L, et al. Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions［J］. Med Comm, 2024, 5(4): e516.
［38］Srivastava A, Tomar B, Sharma D, et al. Mitochondrial dysfunction and oxidative stress: Role in chronic kidney disease［J］. Life Sci, 2023, 319:121432.
［39］Giacco F, Brownlee M. Oxidative stress and diabetic complications［J］. Circ Res, 2010,107(9):1058－1070.
［40］Ni Y H, Zheng L J, Nan S J, et al. Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota［J］. Acta Biochim Biophys Sin, 2022, 54(10): 1406－1420.
［41］Mosterd C M, Kanbay M, Van Den Born B J H, et al. Intestinal microbiota and diabetic kidney diseases: the role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression［J］. Best Pract Res Clin Endocrinol Metab, 2021, 35(3): 101484.
［42］Zhou W, Wu W H, Si Z L, et al. The gut microbe Bacteroides fragilis ameliorates renal fibrosis in mice［J］. Nat Commun, 2022, 13(1): 6081.
［43］Yadegar A, Bar-Yoseph H, Monaghan T M, et al. Fecal microbiota transplantation: current challenges and future landscapes［J］. Clin Microbiol Rev, 2024, 37(2): e0006022.
［44］Rizzetto L, Fava F, Tuohy K M, et al. Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex［J］. J Autoimmun, 2018, 92: 12－34.
［45］Porcari S, Benech N, Valles-Colomer M, et al. Key determinants of success in fecal microbiota transplantation: from microbiome to clinic［J］. Cell Host Microbe, 2023, 31(5): 712－733.
［46］Ding D F, Yong H J, You N, et al. Prospective study reveals host microbial determinants of clinical response to fecal microbiota transplant therapy in type 2 diabetes patients［J］. Front Cell Infect Microbiol, 2022, 12: 820367.
［47］Yang Y, Yan J J, Li S, et al. Efficacy of fecal microbiota transplantation in type 2 diabetes mellitus: a systematic review and meta-analysis［J］. Endocrine, 2024, 84(1): 48－62.
［48］Meng F Y, Zhang F, Meng M, et al. Effects of the synbiotic composed of mangiferin and Lactobacillus reuteri 1－12 on type 2 diabetes mellitus rats［J］. Front Microbiol, 2023, 14: 1158652.
［49］Ross P. Expression of concern: metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial［J］. Food Funct, 2022, 13(7): 4229.
［50］Ma J H, Lv Y H, Liu X, et al. Engineered probiotics［J］. Microb Cell Fact, 2022, 21(1): 72.
［51］Wang X L, Chen W J, Jin R, et al. Engineered probiotics clostridium butyricum-pMTL007-GLP－1 improves blood pressure via producing GLP－1 and modulating gut microbiota in spontaneous hypertension rat models［J］. Microb Biotechnol, 2023, 16(4): 799－812.
［52］Deng F, Zhang L Q, Wu H, et al. Propionate alleviates myocardial ischemia-reperfusion injury aggravated by Angiotensin II dependent on caveolin－1/ACE2 axis through GPR41［J］. Int J Biol Sci, 2022, 18(2): 858－872.
［53］Ma J, Lyu Y, Liu X, et al. Engineered probiotics. Microb Cell Fact, 2022, 21(1):72.
［54］Hu H, Luo J, Liu Y, et al. Improvement effect of a next-generation probiotic L. plantarum-pMG36e-GLP－1 on type 2 diabetes mellitus via the gut-pancreas-liver axis［J］. Food Funct, 2023, 14(7): 3179－3195.
［55］Beam A, Clinger E, Hao L. Effect of diet and dietary components on the composition of the gut microbiota［J］. Nutrients, 2021, 13(8): 2795.
［56］Frazier K, Kambal A, Zale E A, et al. High-fat diet disrupts REG3γ and gut microbial rhythms promoting metabolic dysfunction［J］. Cell Host Microbe, 2022, 30(6): 809－823, e6.
［57］Li Y J, Chen X C, Kwan T K, et al. Dietary fiber protects against diabetic nephropathy through short-chain fatty acid-mediated activation of G protein-coupled receptors GPR43 and GPR109A［J］. J Am Soc Nephrol, 2020, 31(6): 1267－1281.
［58］Nakamura N, Nagawa D, Nakata M, et al. Dietary intake of polyunsaturated fatty acids and diabetic nephropathy: cohort analysis of the Tsugaru study［J］. In Vivo, 2023, 37(4): 1890－1893.
［59］Shapiro H, Theilla M, Attal-Singer J, et al. Effects of polyunsaturated fatty acid consumption in diabetic nephropathy［J］. Nat Rev Nephrol, 2011, 7(2):110－21.
［60］Cheng M H, Ren L L, Jia X X, et al. Understanding the action mechanisms of metformin in the gastrointestinal tract［J］. Front Pharmacol, 2024, 15: 1347047.
［61］Deng L, Yang Y, Xu G S. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota［J］. Biochim Biophys Acta Mol Cell Biol Lipids, 2022, 1867(12): 159234.
［62］Singh H, Miyamoto S, Darshi M, et al. Gut microbial changes in diabetic db/db mice and recovery of microbial diversity upon pirfenidone treatment［J］. Microorganisms, 2020, 8(9): 1347.
［63］Wu X Q, Zhao L, Zhao Y L, et al. Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota［J］. Pharm Biol, 2024, 62(1): 423－435.

[1]	赵苗妙, 李明嘉, 李小亚, 段蕊, 张静宜, 杨金奎. 基于CRISPR/Cas9 技术建立Lepr 与eNos 双基因敲除的糖尿病肾病小鼠模型[J]. 首都医科大学学报, 2024, 45(3): 392-398.
[2]	郑晓敏, 刘梦扬, 肖新华, 崔丽梅, 刘翠平. 维生素D₂对糖尿病肾病患者蛋白尿水平的影响[J]. 首都医科大学学报, 2024, 45(3): 420-428.
[3]	张琳, 谢荣荣, 杨芳远, 李眉, 罗莎, 万晓华, 田玮, 杨金奎. 肾小管及肾小球标志物在2型糖尿病患者不同肾损伤阶段诊断价值的研究[J]. 首都医科大学学报, 2024, 45(3): 429-437.
[4]	李雨阳, 朱晓蓉, 刘婧, 郑晓敏, 杨金奎, 杨芳远. 糖尿病肾病患者触珠蛋白基因多态性及血清触珠蛋白浓度分析[J]. 首都医科大学学报, 2023, 44(3): 375-380.
[5]	李明嘉, 赵苗妙, 杨金奎. 组织蛋白酶在糖尿病及糖尿病肾病作用机制中的研究进展[J]. 首都医科大学学报, 2023, 44(3): 413-419.